Therma Bright's Venowave Accepted for Review By Center for Medicare & Medicaid Services for Permanent CPT and HCPCS Codes
Therma Bright's Venowave Accepted for Review By Center for Medicare & Medicaid Services for Permanent CPT and HCPCS Codes
Company To Resume Trading on Toronto Stock Exchange Venture (TSXV) on February 7, 2024
公司将于2024年2月7日恢复在多伦多证券交易所风险投资（TSXV）的交易
Toronto, Ontario--(Newsfile Corp. - February 6, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, has received a letter from the Center of Medicare and Medicaid. The letter confirms that CMS is reopening the Company's application for its Venowave device for consideration on securing permanent Current Procedural Terminology (CPT) / Healthcare Common Procedure Coding System (HCPCS) codes.
安大略省多伦多--（Newsfile Corp.，2024年2月6日）——一系列领先的专有诊断和医疗设备技术的开发商和合作伙伴Therma Bright Inc.（TSXV：THRM）（OTCQB：TBRIF）（“Therma” 或 “公司”）已收到医疗保险和医疗补助中心的一封信。这封信证实，CMS正在重新开放公司的Venowave设备申请，以考虑保护永久的当前程序术语（CPT）/医疗保健通用程序编码系统（HCPCS）代码。
As outlined in an Official Letter from the Centers for Medicare & Medicaid Services (CMS) to the Company's regulatory advisor -
正如医疗保险和医疗补助服务中心（CMS）给公司监管顾问的正式信函中所概述的那样-
"We have reviewed your request for reconsideration of the final benefit category determination (BCD) for Venowave VW5 and Supplies (Venowave), application #HCP220922Q7MRO.
“我们已经审查了你提出的重审Venowave VW5和Supplies（Venowave）最终福利类别决定（BCD）的申请 #HCP220922Q7MRO。
In the final BCD we stated that Venowave did not fall into a durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) benefit category because it was a single patient use item. DME is defined in Medicare regulations at title 42 Code of Federal Regulations (CFR) 414.202 as equipment furnished by a supplier or a home health agency that meets five conditions, including that of being able to withstand repeated use.
在最后的BCD中，我们指出，Venowave不属于耐用医疗设备、假肢、矫形器和用品（DMEPOS）的福利类别，因为它是一个患者单一使用的项目。医疗保险法规第 42 章《联邦法规法规》(CFR) 414.202 中对二甲苯甲酸甲酯的定义是供应商或家庭健康机构提供的满足五个条件（包括能够承受反复使用的条件）的设备。
Based on the new information provided in your reconsideration request, we believe it is appropriate to re-open your application and to include it in the upcoming First Biannual 2024 HCPCS (B1 2024) cycle. This means that during the B1 2024 cycle we will issue a new preliminary coding decision, BCD, and payment determination; you will have an opportunity to attend and provide comment at the public meeting; and we will then issue a new final determination."
根据您在重审请求中提供的新信息，我们认为重新打开您的申请并将其纳入即将到来的2024年第一半年期HCPCS（B1 2024）周期是适当的。这意味着，在B1 2024周期中，我们将发布新的初步编码决定、BCD和付款决定；您将有机会出席公开会议并在会上发表意见；然后我们将发布新的最终决定。”
In other news, Therma Bright has received notification from the Toronto Stock Exchange Venture (TSXV), that the Company's stock will resume trading on February 7, 2024.
在其他新闻方面，Therma Bright已收到多伦多证券交易所风险投资公司（TSXV）的通知，该公司的股票将于2024年2月7日恢复交易。
About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: .
关于 Therma Bright Inc
Therma Bright是各种前沿专有诊断和医疗设备技术的开发商和合作伙伴，致力于为消费者和医疗专业人员提供优质、创新的解决方案，以应对当今一些最重要的医疗和医疗保健挑战。Therma Bright Inc. 在（多伦多证券交易所股票代码：THRM）（OTCQB：TBRIF）（FSE：JNX）上市。访问：。
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Follow us on Twitter
Therma Bright公司
首席执行官罗伯·菲亚
rfia@thermabright.com
关注我们 推特
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as the receipt of permanent codes from CMS as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
前瞻性陈述
本新闻稿中的某些陈述构成 “前瞻性” 陈述。这些声明与未来的事件有关，例如新闻稿中描述的从CMS收到永久代码的情况。所有这些陈述都涉及大量已知和未知的风险、不确定性和其他因素，这些因素可能导致实际结果与此类前瞻性陈述所表达或暗示的结果有所不同。前瞻性陈述涉及重大风险和不确定性，不应将其视为对未来业绩或业绩的保证，也不一定能准确表明是否会取得此类成果。由于多种因素和风险，实际结果可能与预期有重大差异。尽管本新闻稿中包含的前瞻性陈述基于公司管理层在本新闻发布之日认为的合理假设，但公司无法向投资者保证实际业绩将与这些前瞻性陈述一致。本新闻稿中包含的前瞻性陈述自发布之日起作出，除非适用的证券法规要求，否则公司不打算或有义务更新或修改任何前瞻性陈述，无论是由于新信息、未来事件还是其他原因。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
多伦多证券交易所风险投资交易所及其监管服务提供商（该术语在多伦多证券交易所风险投资交易所的政策中定义）均不对本新闻稿的充分性或准确性承担责任。
译文内容由第三方软件翻译。